Adverse Drug Reactions with Drugs Used in Multiple Sclerosis: An Analysis from the Italian Pharmacovigilance Database
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Adverse Drug Reactions with Drugs Used in Multiple Sclerosis: An Analysis from the Italian Pharmacovigilance Database
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 13, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-02-23
DOI
10.3389/fphar.2022.808370
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Adverse drug reactions with oral anticoagulants: data from sicilian spontaneous reporting system database
- (2021) Maria Antonietta Barbieri et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- Association Between Disease-Modifying Therapies Prescribed to Persons with Multiple Sclerosis and Cancer: a WHO Pharmacovigilance Database Analysis
- (2021) Charles Dolladille et al. Neurotherapeutics
- Adverse Drug Reactions with HER2-Positive Breast Cancer Treatment: An Analysis from the Italian Pharmacovigilance Database
- (2021) Maria Antonietta Barbieri et al. Drugs - Real World Outcomes
- Cancer Risk for Fingolimod, Natalizumab, and Rituximab in MS Patients
- (2020) Peter Alping et al. ANNALS OF NEUROLOGY
- Fingolimod and Dimethyl-Fumarate-Derived Lymphopenia is not Associated with Short-Term Treatment Response and Risk of Infections in a Real-Life MS Population
- (2020) Giacomo Boffa et al. CNS DRUGS
- Multiple Sclerosis Treatment and Melanoma Development
- (2020) Maria Luigia Carbone et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP)
- (2020) Helmut Butzkueven et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Lipoprotein profiling in early multiple sclerosis patients: effect of chronic inflammation?
- (2020) Žofia Rádiková et al. Lipids in Health and Disease
- Acute cardiotoxicity associated with alemtuzumab infusion for multiple sclerosis
- (2020) Dariush Ahrabian et al. Multiple Sclerosis Journal
- Lipid Profile Alterations during Fingolimod Treatment in Multiple Sclerosis Patients
- (2020) Ilkka Rauma et al. Journal of Neuroimmune Pharmacology
- Managing Risks with Immune Therapies in Multiple Sclerosis
- (2019) Moritz Förster et al. DRUG SAFETY
- Correction to: The Italian multiple sclerosis register
- (2019) Maria Trojano et al. NEUROLOGICAL SCIENCES
- Dimethyl fumarate, a two-edged drug: Current status and future directions
- (2019) Nathaniel Edward Bennett Saidu et al. MEDICINAL RESEARCH REVIEWS
- Teriflunomide: A Review in Relapsing–Remitting Multiple Sclerosis
- (2019) Lesley J. Scott DRUGS
- Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing–remitting multiple sclerosis: a systematic review and network meta-analysis
- (2019) Huihui Li et al. JOURNAL OF NEUROLOGY
- Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD)
- (2019) Sandra Vukusic et al. Multiple Sclerosis and Related Disorders
- Potential mechanisms of action related to the efficacy and safety of cladribine
- (2019) David Baker et al. Multiple Sclerosis and Related Disorders
- The Role of Monocytes and Macrophages in Autoimmune Diseases: A Comprehensive Review
- (2019) Wen-Tao Ma et al. Frontiers in Immunology
- Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility
- (2019) SCIENCE
- Two cases of meningitis associated with ocrelizumab therapy
- (2019) Michael Theriault et al. Multiple Sclerosis and Related Disorders
- The value of oligoclonal bands in the multiple sclerosis diagnostic criteria
- (2018) Georgina Arrambide et al. BRAIN
- Efficacy and Safety of the Newer Multiple Sclerosis Drugs Approved Since 2010
- (2018) Simon Faissner et al. CNS DRUGS
- Disease-modifying treatments for early and advanced multiple sclerosis
- (2018) Gavin Giovannoni CURRENT OPINION IN NEUROLOGY
- Managing the side effects of multiple sclerosis therapy: pharmacotherapy options for patients
- (2018) Paulus S. Rommer et al. EXPERT OPINION ON PHARMACOTHERAPY
- Interferon-beta injection site reactions in patients with multiple sclerosis
- (2018) Martina Maurelli et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Cladribine: mechanisms and mysteries in multiple sclerosis
- (2018) Benjamin Meir Jacobs et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Multiple Sclerosis
- (2018) Raed Alroughani et al. SEMINARS IN NEUROLOGY
- Ocrelizumab: A Review in Multiple Sclerosis
- (2018) Yahiya Y. Syed CNS DRUGS
- Cancer Risk in Patients with Multiple Sclerosis: Potential Impact of Disease-Modifying Drugs
- (2018) Christine Lebrun et al. CNS DRUGS
- Treatment of multiple sclerosis — success from bench to bedside
- (2018) Mar Tintore et al. Nature Reviews Neurology
- Lymphopenia and risk of infection and infection-related death in 98,344 individuals from a prospective Danish population-based study
- (2018) Marie Warny et al. PLOS MEDICINE
- Multiple sclerosis
- (2018) Massimo Filippi et al. Nature Reviews Disease Primers
- Natalizumab in Multiple Sclerosis: Long-Term Management
- (2017) Marinella Clerico et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations
- (2017) Gabriel Pardo et al. JOURNAL OF NEUROLOGY
- Comorbidity increases the risk of relapse in multiple sclerosis
- (2017) Kaarina Kowalec et al. NEUROLOGY
- Comparison of efficacy and safety of oral agents for the treatment of relapsing–remitting multiple sclerosis
- (2017) Cristina Guarnera et al. Drug Design Development and Therapy
- Drug-induced progressive multifocal leukoencephalopathy: Lessons learned from contrasting natalizumab and rituximab
- (2015) NS Vermeer et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Dimethyl Fumarate Inhibits the Nuclear Factor κB Pathway in Breast Cancer Cells by Covalent Modification of p65 Protein
- (2015) Irida Kastrati et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Why does multiple sclerosis only affect human primates?
- (2015) Bert A ‘t Hart Multiple Sclerosis Journal
- A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview
- (2015) Ruth Ann Marrie et al. Multiple Sclerosis Journal
- Why does multiple sclerosis only affect human primates?
- (2015) Bert A ‘t Hart Multiple Sclerosis Journal
- A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview
- (2015) Ruth Ann Marrie et al. Multiple Sclerosis Journal
- Vascular comorbidities in the onset and progression of multiple sclerosis
- (2014) Prudence Tettey et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2014) Peter A Calabresi et al. LANCET NEUROLOGY
- WHO Strategy for Collecting Safety Data in Public Health Programmes: Complementing Spontaneous Reporting Systems
- (2013) Shanthi N. Pal et al. DRUG SAFETY
- Dendritic cells in multiple sclerosis: key players in the immunopathogenesis, key players for new cellular immunotherapies?
- (2013) AH Nuyts et al. Multiple Sclerosis Journal
- Progressive Multifocal Leukoencephalopathy in Patients on Immunomodulatory Therapies
- (2009) Eugene O. Major Annual Review of Medicine
- Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a
- (2009) R. A. Rudick et al. NEUROLOGY
- Multiple sclerosis
- (2008) Alastair Compston et al. LANCET
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now